{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:50:55Z","timestamp":1792698655654,"version":"4.5.0"},"reference-count":122,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Obesity and metabolic syndrome (MS) represent two of the most pressing global public health challenges, often coexisting and synergistically increasing the risk of cardiovascular and renal complications. Over the past decade, advances in our understanding of the pathophysiological mechanisms underlying chronic kidney disease (CKD) have reshaped our approach to patients with coexisting obesity and CKD. The identification of distinct phenotypes associated with an elevated risk of CKD progression and cardiovascular events, along with the development of novel therapeutic strategies, has contributed to a paradigm shift in clinical management. Currently, therapeutic options such as sodium\u2013glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and their combination with the non-steroidal mineralocorticoid receptor antagonist finerenone\u2014when added to standard renin\u2013angiotensin\u2013aldosterone system blockade\u2014are available and have shown potential for cardiorenal protection in patients with obesity and\/or MS and CKD. In this review, we highlight the complex interplay between obesity and CKD, emphasizing the need for an integrated, multidisciplinary approach. The use of multitargeted therapeutic strategies holds promise in substantially altering the natural course of disease progression, ultimately improving patient outcomes.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf231","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:16:36Z","timestamp":1761830196000},"page":"846-858","source":"Crossref","is-referenced-by-count":7,"title":["Obesity as a modifiable risk factor in patients with chronic kidney disease"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-6973","authenticated-orcid":false,"given":"Enrique","family":"Morales","sequence":"first","affiliation":[{"name":"Hospital 12 de Octubre Department of Nephrology, , Madrid ,","place":["Spain"]},{"name":"Research Institute of University Hospital 12 de Octubre (imas12), RICORS2040-Renal Network, ISCIII , Madrid ,","place":["Spain"]},{"name":"Complutense University of Madrid Department of Medicine, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond G","family":"Jenssen","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Oslo University Hospital Rikshospitalet Department of Transplantation Medicine, , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastjan","family":"Bevc","sequence":"additional","affiliation":[{"name":"Clinic for Internal Medicine, University Medical Centre Maribor Department of Nephrology, , Maribor ,","place":["Slovenia"]},{"name":"Medical Faculty, University of Maribor , Maribor ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Miglinas","sequence":"additional","affiliation":[{"name":"Center of Nephrology, Santaros Klinikos, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University , Vilnius ,","place":["Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P","family":"Martin","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis Division of Nephrology, Department of Medicine, , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6216-9635","authenticated-orcid":false,"given":"Marieta","family":"Theodorakopoulou","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki First Department of Nephrology, Hippokration Hospital, , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Buus J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Inge Lehmanns Vej 7 Department of Nephrology and Endocrinology, 2131 Rigshospitalet, , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Trillini","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2026043010391741600_bib1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"2026043010391741600_bib2","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Brauer","year":"2024","journal-title":"Lancet"},{"key":"2026043010391741600_bib3","doi-asserted-by":"publisher","first-page":"e009773","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe","year":"2022","journal-title":"BMJ Glob Health"},{"key":"2026043010391741600_bib4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","journal-title":"N Engl J Med"},{"key":"2026043010391741600_bib5","first-page":"450","article-title":"Obesity, insulin resistance and kidney disease risk: insights into the relationship","volume-title":"Curr Opin Nephrol Hypertens","author":"Sarafidis","year":"2008"},{"key":"2026043010391741600_bib6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.kint.2016.12.013","article-title":"A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population","volume":"91","author":"Garofalo","year":"2017","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib7","doi-asserted-by":"publisher","first-page":"k5301","DOI":"10.1136\/bmj.k5301","article-title":"Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium","volume":"364","author":"Chang","year":"2019","journal-title":"BMJ"},{"key":"2026043010391741600_bib8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"2026043010391741600_bib9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death","volume":"49","author":"Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026043010391741600_bib10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00125-005-1873-5","article-title":"The myth of the metabolic syndrome","volume":"48","author":"Gale","year":"2005","journal-title":"Diabetologia"},{"key":"2026043010391741600_bib11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.kint.2024.12.021","article-title":"The prevention and management of chronic kidney disease among patients with metabolic syndrome","volume":"107","author":"Zhu","year":"2025","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000545356","article-title":"Association of obesity-related indices with rapid kidney function decline and chronic kidney disease: a study from a large longitudinal cohort in China","volume":"18","author":"Yang","year":"2025","journal-title":"Obes Facts"},{"key":"2026043010391741600_bib13","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1111\/dom.15874","article-title":"Degree of joint risk factor control and incident chronic kidney disease among individuals with obesity","volume":"26","author":"Tang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026043010391741600_bib14","doi-asserted-by":"publisher","first-page":"1563164","DOI":"10.3389\/fendo.2025.1563164","article-title":"Baseline comorbidity of cardiovascular-kidney-metabolic syndrome increases the risk of adverse clinical outcomes in patients with chronic kidney disease","volume":"16","author":"Meng","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026043010391741600_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","article-title":"Body mass index and risk for end-stage renal disease","volume":"144","author":"Hsu","year":"2006","journal-title":"Ann Intern Med"},{"key":"2026043010391741600_bib16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.ki.5002160","article-title":"Glomerular hyperfiltration: a new marker of metabolic risk","volume":"71","author":"Tomaszewski","year":"2007","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12882-016-0386-4","article-title":"Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study","volume":"17","author":"Stefansson","year":"2016","journal-title":"BMC Nephrol"},{"key":"2026043010391741600_bib18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.kint.2017.11.012","article-title":"Metabolic syndrome but not obesity measures are risk factors for accelerated age-related glomerular filtration rate decline in the general population","volume":"93","author":"Stefansson","year":"2018","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1681\/ASN.2021091263","article-title":"The association of excess body weight with risk of ESKD is mediated through insulin resistance, hypertension, and hyperuricemia","volume":"33","author":"Fritz","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026043010391741600_bib20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ndt\/gfp483","article-title":"Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey","volume":"25","author":"Yu","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010391741600_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D\u2019Agati","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2026043010391741600_bib22","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.3390\/ijms24097898","article-title":"Mechanisms of oxidative stress in metabolic syndrome","volume":"24","author":"Masenga","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026043010391741600_bib23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.drudis.2021.11.001","article-title":"Obesity and insulin resistance: pathophysiology and treatment","volume":"27","author":"Tong","year":"2022","journal-title":"Drug Discov Today"},{"key":"2026043010391741600_bib24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1152\/physiol.00041.2015","article-title":"Linking gut microbiota and inflammation to obesity and insulin resistance","volume":"31","author":"Saad","year":"2016","journal-title":"Physiology"},{"key":"2026043010391741600_bib25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrendo.2012.114","article-title":"Adaptive immunity in obesity and insulin resistance","volume":"8","author":"Sell","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2026043010391741600_bib26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026043010391741600_bib27","doi-asserted-by":"publisher","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026043010391741600_bib28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2337\/db16-0607","article-title":"Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial","volume":"66","author":"Ruggenenti","year":"2017","journal-title":"Diabetes"},{"key":"2026043010391741600_bib29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2337\/dc23-1420","article-title":"Outcomes with finerenone in patients with chronic kidney disease and type 2 diabetes by baseline insulin resistance","volume":"47","author":"Ebert","year":"2024","journal-title":"Diabetes Care"},{"key":"2026043010391741600_bib30","doi-asserted-by":"publisher","first-page":"655871","DOI":"10.3389\/fmed.2021.655871","article-title":"A nephrologist perspective on obesity: from kidney injury to clinical management","volume":"8","author":"Garc\u00eda-Carro","year":"2021","journal-title":"Front Med"},{"key":"2026043010391741600_bib31","doi-asserted-by":"publisher","first-page":"e13450","DOI":"10.1111\/obr.13450","article-title":"Obesity-related glomerulopathy: current approaches and future perspectives","volume":"23","author":"Mart\u00ednez-Montoro","year":"2022","journal-title":"Obes Rev"},{"key":"2026043010391741600_bib32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ndt\/gfh015","article-title":"Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease","volume":"19","author":"Stehouwer","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010391741600_bib33","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc07-0525","article-title":"Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients","volume":"30","author":"Colussi","year":"2007","journal-title":"Diabetes Care"},{"key":"2026043010391741600_bib34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2215\/CJN.08980914","article-title":"Metabolically healthy obesity and risk of incident CKD","volume":"10","author":"Hashimoto","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026043010391741600_bib35","doi-asserted-by":"publisher","first-page":"804719","DOI":"10.3389\/fnut.2022.804719","article-title":"Advances in phenotyping obesity and in its dietary and pharmacological treatment: a narrative review","volume":"9","author":"Pujia","year":"2022","journal-title":"Front Nutr"},{"key":"2026043010391741600_bib36","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/oby.22134","article-title":"Metabolically healthy obesity and risk of kidney function decline","volume":"26","author":"Chang","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2026043010391741600_bib37","first-page":"2007","article-title":"Metabolically healthy obesity and risk of incident chronic kidney disease in a Korean cohort study","volume":"48","author":"Yang","year":"2019","journal-title":"Iran J Public Health"},{"key":"2026043010391741600_bib38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.ajkd.2021.05.008","article-title":"Obesity without metabolic abnormality and incident CKD: a population-based British cohort study","volume":"79","author":"Wang","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026043010391741600_bib39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejim.2023.02.025","article-title":"Metabolically healthy obesity: misleading phrase or healthy phenotype?","volume":"111","author":"Tanriover","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2026043010391741600_bib40","doi-asserted-by":"publisher","first-page":"e13656","DOI":"10.1111\/obr.13656","article-title":"Risk of incident chronic kidney disease in metabolically healthy obesity and metabolically unhealthy normal weight: a systematic review and meta-analysis","volume":"25","author":"Iqbal","year":"2024","journal-title":"Obes Rev"},{"key":"2026043010391741600_bib41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026043010391741600_bib42","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s11255-019-02320-0","article-title":"Metabolic syndrome is a predictor of decreased renal function among community-dwelling middle-aged and elderly Japanese","volume":"51","author":"Kawamoto","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2026043010391741600_bib43","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1210\/clinem\/dgab633","article-title":"Causal associations of obesity with chronic kidney disease and arterial stiffness: a Mendelian randomization study","volume":"107","author":"Ye","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026043010391741600_bib44","doi-asserted-by":"publisher","first-page":"100982","DOI":"10.1016\/j.xkme.2025.100982","article-title":"Body mass index in late adolescence and later life kidney outcomes: a population-based cohort study in Swedish men","volume":"7","author":"Vitkauskait\u0117","year":"2025","journal-title":"Kidney Med"},{"key":"2026043010391741600_bib45","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.ajkd.2013.03.032","article-title":"Early-life overweight trajectory and CKD in the 1946 British Birth Cohort Study","volume":"62","author":"Silverwood","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026043010391741600_bib46","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1681\/ASN.2005060638","article-title":"Obesity and risk for chronic renal failure","volume":"17","author":"Ejerblad","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026043010391741600_bib47","doi-asserted-by":"crossref","first-page":"e1004098","DOI":"10.1371\/journal.pmed.1004098","article-title":"Childhood body mass index trajectories and associations with adult-onset chronic kidney disease in Denmark: a population-based cohort study","volume":"19","author":"Aarestrup","year":"2022","journal-title":"PLoS Med"},{"key":"2026043010391741600_bib48","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1159\/000546354","article-title":"What is the role of sex differences in obesity-associated chronic kidney disease?","volume":"149","author":"Sandino-P\u00e9rez","year":"2025","journal-title":"Nephron"},{"key":"2026043010391741600_bib49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3892\/mmr.2025.13629","article-title":"Role of obesity and estrogen deficiency in non\u2011alcoholic fatty liver disease: insights from a mouse model","volume":"32","author":"Afonso-Al\u00ed","year":"2025","journal-title":"Mol Med Rep"},{"key":"2026043010391741600_bib50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-023-00784-z","article-title":"Differences in the epidemiology, management and outcomes of kidney disease in men and women","volume":"20","author":"Chesnaye","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026043010391741600_bib51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/CIRCRESAHA.124.325535","article-title":"Sex-specific factors influencing obesity in women: bridging the gap between science and clinical practice","volume":"136","author":"Ayesh","year":"2025","journal-title":"Circ Res"},{"key":"2026043010391741600_bib52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/kisup.2014.21","article-title":"Obesity, oxidative stress, and fibrosis in chronic kidney disease","volume":"4","author":"Sharma","year":"2014","journal-title":"Kidney Int Suppl"},{"key":"2026043010391741600_bib53","doi-asserted-by":"publisher","first-page":"30996","DOI":"10.1038\/s41598-024-81929-3","article-title":"The impact of metabolic component count on IgA nephropathy prognosis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"2026043010391741600_bib54","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12882-019-1434-7","article-title":"Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases","volume":"20","author":"Elyan","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026043010391741600_bib55","doi-asserted-by":"publisher","first-page":"1094534","DOI":"10.3389\/fendo.2023.1094534","article-title":"Association of obesity with the development of end stage renal disease in IgA nephropathy patients","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026043010391741600_bib56","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.kint.2018.11.026","article-title":"The spectrum of kidney biopsy findings in patients with morbid obesity","volume":"95","author":"Choung","year":"2019","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib57","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000513869","article-title":"Association of obesity with cardiovascular risk factors and kidney disease outcomes in primary proteinuric glomerulopathies","volume":"145","author":"Shah","year":"2021","journal-title":"Nephron"},{"key":"2026043010391741600_bib58","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/DMSO.S366100","article-title":"Correlation of body mass index with clinicopathologic parameters in patients with idiopathic membranous nephropathy","volume":"15","author":"Chen","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026043010391741600_bib59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1053\/j.ajkd.2024.03.020","article-title":"Association of obesity with kidney and cardiac outcomes among patients with glomerular disease: findings from the Cure Glomerulonephropathy Network","volume":"84","author":"Zeitler","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026043010391741600_bib60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1053\/j.ajkd.2024.02.014","article-title":"Visceral adiposity and progression of ADPKD: a cohort study of patients from the TEMPO 3:4 Trial","volume":"84","author":"Nowak","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026043010391741600_bib61","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"key":"2026043010391741600_bib62","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"2026043010391741600_bib63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL\u2013Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"2026043010391741600_bib64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026043010391741600_bib65","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"2026043010391741600_bib66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000528080","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease","volume":"147","author":"Adrian","year":"2023","journal-title":"Nephron"},{"key":"2026043010391741600_bib67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"key":"2026043010391741600_bib68","doi-asserted-by":"publisher","first-page":"101512","DOI":"10.1016\/j.aohep.2024.101512","article-title":"MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease","volume":"29","author":"Pan","year":"2024","journal-title":"Ann Hepatol"},{"key":"2026043010391741600_bib69","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/ndt\/gfaf069","article-title":"How to individualise renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA","volume":"40","author":"Morales","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010391741600_bib70","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2215\/CJN.02250409","article-title":"Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026043010391741600_bib71","doi-asserted-by":"crossref","first-page":"e009348","DOI":"10.1161\/CIRCOUTCOMES.122.009348","article-title":"Long-term effect of weight regain following behavioral weight management programs on cardiometabolic disease incidence and risk: systematic review and meta-analysis","volume":"16","author":"Hartmann-Boyce","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026043010391741600_bib72","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"key":"2026043010391741600_bib73","doi-asserted-by":"publisher","first-page":"e069719","DOI":"10.1136\/bmj-2021-069719","article-title":"Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials","volume":"377","author":"Madigan","year":"2022","journal-title":"BMJ"},{"key":"2026043010391741600_bib74","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/jama.2018.0245","article-title":"Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial","volume":"319","author":"Gardner","year":"2018","journal-title":"JAMA"},{"issue":"4S","key":"2026043010391741600_bib75","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib76","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrneph.2016.187","article-title":"Physical inactivity: a risk factor and target for intervention in renal care","volume":"13","author":"Zelle","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026043010391741600_bib77","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/sj.ijo.0800499","article-title":"A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention","volume":"21","author":"Miller","year":"1997","journal-title":"Int J Obes"},{"key":"2026043010391741600_bib78","doi-asserted-by":"publisher","first-page":"e054887","DOI":"10.1136\/bmjopen-2021-054887","article-title":"Therapeutic effects of exercise interventions for patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses","volume":"12","author":"Zhang","year":"2022","journal-title":"BMJ Open"},{"key":"2026043010391741600_bib79","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehn387","article-title":"Adipose tissue dysfunction in obesity, diabetes, and vascular diseases","volume":"29","author":"Hajer","year":"2008","journal-title":"Eur Heart J"},{"key":"2026043010391741600_bib80","doi-asserted-by":"publisher","first-page":"F473","DOI":"10.1152\/ajprenal.00503.2013","article-title":"The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis","volume":"306","author":"Grabias","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026043010391741600_bib81","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"P\u00e1lsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026043010391741600_bib82","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/ph17040418","article-title":"Finerenone: From the mechanism of action to clinical use in kidney disease","volume":"17","author":"Piko","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026043010391741600_bib83","doi-asserted-by":"publisher","first-page":"gfaf119","DOI":"10.1093\/ndt\/gfaf119","article-title":"Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial","author":"Mark","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010391741600_bib84","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium\u2013glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int"},{"key":"2026043010391741600_bib85","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2026043010391741600_bib86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ehjcvp\/pvae094","article-title":"Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study","volume":"11","author":"Jimba","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026043010391741600_bib87","doi-asserted-by":"publisher","first-page":"e004876","DOI":"10.1136\/bmjdrc-2024-004876","article-title":"SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index","volume":"13","author":"Lee","year":"2025","journal-title":"BMJ Open Diab Res Care"},{"key":"2026043010391741600_bib88","doi-asserted-by":"publisher","first-page":"1398059","DOI":"10.3389\/fnut.2024.1398059","article-title":"Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity","volume":"11","author":"Tamayo-Trujillo","year":"2024","journal-title":"Front Nutr"},{"key":"2026043010391741600_bib89","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.diabres.2018.05.034","article-title":"The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: a systematic review and meta-analysis","volume":"142","author":"Maciel","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2026043010391741600_bib90","doi-asserted-by":"publisher","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP\u22121 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026043010391741600_bib91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/ndt\/gfaf008","article-title":"The future of glucagon-like peptide-1 receptor agonists in cardiovascular\u2013kidney\u2013metabolic diseases considerations from the ERA Diabesity Working Group","volume":"40","author":"Trillini","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010391741600_bib92","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026043010391741600_bib93","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"2026043010391741600_bib94","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026043010391741600_bib95","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"2026043010391741600_bib96","doi-asserted-by":"publisher","first-page":"170749","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells\u2014a review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"2026043010391741600_bib97","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2026043010391741600_bib98","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP Enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2026043010391741600_bib99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026043010391741600_bib100","doi-asserted-by":"publisher","first-page":"2042018819865398","DOI":"10.1177\/2042018819865398","article-title":"The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists","volume":"10","author":"Van Baar","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026043010391741600_bib101","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/dc24-1773","article-title":"Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1\u20135 clinical trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"key":"2026043010391741600_bib102","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026043010391741600_bib103","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026043010391741600_bib104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000371557","article-title":"Estimated GFR is biased by non-traditional cardiovascular risk factors","volume":"41","author":"Melsom","year":"2015","journal-title":"Am J Nephrol"},{"key":"2026043010391741600_bib105","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.ekir.2025.03.049","article-title":"The effect of retatrutide on kidney parameters in participants with type 2 diabetes mellitus and\/or obesity","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"Suppl 1","key":"2026043010391741600_bib106","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2337\/db24-754-P","article-title":"754-P: effect of retatrutide on kidney parameters in people with type 2 diabetes and\/or obesity\u2014a post-hoc analysis of two phase 2 trials","volume":"73","author":"Heerspink","year":"2024","journal-title":"Diabetes"},{"key":"2026043010391741600_bib107","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12020-024-03998-8","article-title":"Comparison of the effects of liraglutide, tirzepatide, and retatrutide on diabetic kidney disease in db\/db mice","volume":"87","author":"Ma","year":"2024","journal-title":"Endocrine"},{"key":"2026043010391741600_bib108","article-title":"A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of retatrutide on the incidence of major adverse cardiovascular events and major adverse kidney events in participants with body mass index \u226527\u00a0kg\/m2 and atherosclerotic cardiovascular disease and\/or chronic kidney disease","author":"Eli Lilly and Company"},{"key":"2026043010391741600_bib109","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s13679-024-00583-y","article-title":"The kidney in obesity: current evidence, perspectives and controversies","volume":"13","author":"Kounatidis","year":"2024","journal-title":"Curr Obes Rep"},{"key":"2026043010391741600_bib110","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/17512433.2025.2450254","article-title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","volume":"18","author":"Tewari","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026043010391741600_bib111","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1007\/s11695-024-07196-3","article-title":"Metabolic bariatric surgery across the IFSO chapters: key insights on the baseline patient demographics, procedure types, and mortality from the Eighth IFSO Global Registry Report","volume":"34","author":"Brown","year":"2024","journal-title":"Obes Surg"},{"key":"2026043010391741600_bib112","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1159\/000511790","article-title":"Impact of metabolic surgery on renal injury in pre-clinical models of diabetic kidney disease","volume":"145","author":"Martin","year":"2021","journal-title":"Nephron"},{"key":"2026043010391741600_bib113","doi-asserted-by":"publisher","first-page":"757228","DOI":"10.3389\/fendo.2021.757228","article-title":"Medications activating tubular fatty acid oxidation enhance the protective effects of Roux-en-Y gastric bypass surgery in a rat model of early diabetic kidney disease","volume":"12","author":"Martin","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026043010391741600_bib114","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00125-019-4816-2","article-title":"Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study","volume":"62","author":"Madsen","year":"2019","journal-title":"Diabetologia"},{"key":"2026043010391741600_bib115","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/ijo.2014.72","article-title":"The incidence of albuminuria after bariatric surgery and usual care in Swedish obese subjects (SOS): a prospective controlled intervention trial","volume":"39","author":"Carlsson","year":"2015","journal-title":"Int J Obes"},{"key":"2026043010391741600_bib116","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1681\/ASN.2017060707","article-title":"Effect of bariatric surgery on CKD risk","volume":"29","author":"Friedman","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026043010391741600_bib117","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"2026043010391741600_bib118","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"},{"key":"2026043010391741600_bib119","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/metabo12020139","article-title":"Urinary metabolomic changes accompanying albuminuria remission following gastric bypass surgery for type 2 diabetic kidney disease","volume":"12","author":"Martin","year":"2022","journal-title":"Metabolites"},{"key":"2026043010391741600_bib120","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"2026043010391741600_bib121","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026043010391741600_bib122","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf231\/65042068\/gfaf231.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/5\/846\/65042068\/gfaf231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/5\/846\/65042068\/gfaf231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:39:23Z","timestamp":1777559963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/5\/846\/8306859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":122,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf231","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,30]]}}}